Abstract
Major depressive disorder (MDD) has been associated with an increased risk of subsequent Parkinson’s disease (PD) in case–control and cohort studies. However, depression alone is unlikely to be a useful marker of prodromal PD due to its low specificity. In this longitudinal observational study, we assessed whether the presence of other potential markers of prodromal PD predicts the subsequent development of PD in MDD patients. Of 57 patients with severe MDD but no diagnosis of PD who underwent a structured interview, olfactory and motor investigation and transcranial sonography at baseline, 46 (36 women; mean age 54.9 ± 11.7 years) could be followed for up to 11 (median, 10) years. Three patients (2 women; age 64, 65 and 70 years) developed definite PD after 1, 7, and 9 years, respectively. The combined finding of mild asymmetric motor slowing, idiopathic hyposmia, and substantia nigra hyperechogenicity predicted subsequent PD in all patients who could be followed for longer than 1 year. Out of the whole study cohort, only the subjects with subsequent PD presented with the triad of asymmetric motor slowing, idiopathic hyposmia, and substantia nigra hyperechogenicity in combination with at least two out of four reportable risk factors (family history of PD, current non-smoker, non-coffee drinker, constipation) at baseline investigation. Post-hoc analysis revealed that additional rating of eye and eye-lid motor abnormalities might further improve the prediction of PD in larger cohorts. Findings of this pilot-study suggest that MDD patients at risk of subsequent PD can be identified using an inexpensive non-invasive diagnostic battery.
Similar content being viewed by others
References
Abbott RD, Petrovitch H, White LR et al (2001) Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 57:456–462
Alonso A, Rodríguez LA, Logroscino G, Hernán MA (2009) Use of antidepressants and the risk of Parkinson’s disease: a prospective study. J Neurol Neurosurg Psychiatry 80:671–674
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington
Barone P, Antonini A, Colosimo C et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571
Becker G, Müller A, Braune S et al (2002) Early diagnosis of Parkinson’s disease. J Neurol 249(suppl 3):40–48
Berg D, Becker G, Zeiler B et al (1999) Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 53:1026–1031
Berg D, Marek K, Ross GW, Poewe W (2012) Defining at-risk populations for Parkinson’s disease: lessons from ongoing studies. Mov Disord 27:656–665
Berg D, Behnke S, Seppi K et al (2013) Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson’s disease. Mov Disord 28:216–219
Berg D, Postuma RB, Bloem B et al (2014) Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov Disord 29:454–462
Bologna M, Fabbrini G, Marsili L, Defazio G, Thompson PD, Berardelli A (2013) Facial bradykinesia. J Neurol Neurosurg Psychiatry 84:681–685
Busse K, Heilmann R, Kleinschmidt S et al (2012) Value of combined midbrain sonography, olfactory and motor function assessment in the differential diagnosis of early Parkinson’s disease. J Neurol Neurosurg Psychiatry 83:441–447
Daum RF, Sekinger B, Kobal G, Lang CJ (2000) Olfactory testing with “sniffin’ sticks” for clinical diagnosis of Parkinson disease. Nervenarzt 71:643–650
Fahn S, Elton RL, Members of the UPDRS Development Committee (1987) Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB (eds) Recent developments in Parkinson´s disease II, 1st edn. Macmillan, New York, pp 153–163
Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198
Gaenslen A, Wurster I, Brockmann K et al (2014) Prodromal features for Parkinson’s disease—baseline data from the TREND study. Eur J Neurol 21:766–772
Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51:745–752
Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278–296
Hassin-Baer S, Sirota P, Korczyn AD et al (2001) Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm 108:1299–1308
Hernán MA, Takkouche B, Caamaño-Isorna F, Gestal-Otero JJ (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol 52:276–284
Hoeppner J, Prudente-Morrissey L, Herpertz SC, Benecke R, Walter U (2009) Substantia nigra hyperechogenicity in depressive subjects relates to motor asymmetry and impaired word fluency. Eur Arch Psychiatry Clin Neurosci 259:92–97
Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G (1997) ‘Sniffin’ sticks’: olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses 22:39–52
Iranzo A, Lomeña F, Stockner H et al (2010) Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 9:1070–1077
Ishihara-Paul L, Wainwright NW, Khaw KT et al (2008) Prospective association between emotional health and clinical evidence of Parkinson’s disease. Eur J Neurol 15:1148–1154
Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR (2003) Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord 18:414–418
Lees AJ, Hardy J, Revesz T (2009) Parkinson’s disease. Lancet 373:2055–2066
Lerche S, Seppi K, Behnke S et al (2014) Risk factors and prodromal markers and the development of Parkinson’s disease. J Neurol 261:180–187
Liepelt-Scarfone I, Behnke S, Godau J, Schweitzer KJ, Wolf B, Gaenslen A, Berg D (2011) Relation of risk factors and putative premotor markers for Parkinson’s disease. J Neural Transm 118:579–585
Lin HL, Lin HC, Chen YH (2014) Psychiatric diseases predated the occurrence of Parkinson disease: a retrospective cohort study. Ann Epidemiol 24:206–213
Meyer JH, McNeely HE, Sagrati S et al (2006) Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. Am J Psychiatry 163:1594–1602
Murray CJ, Vos T, Lozano R et al (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2197–2223
Nilsson FM, Kessing LV, Bolwig TG (2001) Increased risk of developing Parkinson’s disease for patients with major affective disorder: a register study. Acta Psychiatr Scand 104:380–386
Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, Schrag A (2012) Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 72:893–901
Oehme L, Perick M, Beuthien-Baumann B et al (2011) Comparison of dopamine turnover, dopamine influx constant and activity ratio of striatum and occipital brain with 18F-dopa brain PET in normal controls and patients with Parkinson’s disease. Eur J Nucl Med Mol Imaging 38:1550–1559
O’Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ (2008) Nonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study. Mov Disord 23:101–106
Pause BM, Miranda A, Göder R, Aldenhoff JB, Ferstl R (2001) Reduced olfactory performance in patients with major depression. J Psychiatr Res 35:271–277
Postuma RB, Aarsland D, Barone P, Burn DJ, Hawkes CH, Oertel W, Ziemssen T (2012) Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord 27:617–626
Sobin C, Mayer L, Endicott J (1998) The motor agitation and retardation scale: a scale for the assessment of motor abnormalities in depressed patients. J Neuropsychiatry Clin Neurosci 10:85–92
Srivastava A, Tang MX, Mejia-Santana H et al (2011) The relation between depression and parkin genotype: the CORE-PD study. Parkinsonism Relat Disord 17:740–744
Starkstein SE, Petracca G, Tesón A et al (1996) Catatonia in depression: prevalence, clinical correlates, and validation of a scale. J Neurol Neurosurg Psychiatry 60:326–332
Stern MB, Siderowf A (2010) Parkinson’s at risk syndrome: can Parkinson’s disease be predicted? Mov Disord 25(suppl 1):89–93
Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA (1999) Functional bowel disorders and functional abdominal pain. Gut 45(suppl 2):43–47
Todd G, Haberfield M, Faulkner PL et al (2014) Hand function is impaired in healthy older adults at risk of Parkinson’s disease. J Neural Transm. doi:10.1007/s00702-014-1218-y
Walter U, Hoeppner J, Prudente-Morrissey L, Horowski S, Herpertz SC, Benecke R (2007) Parkinson’s disease-like midbrain sonography abnormalities are frequent in depressive disorders. Brain 130:1799–1807
Walter U, Kleinschmidt S, Rimmele F, Wunderlich C, Gemende I, Benecke R, Busse K (2013) Potential impact of self-perceived prodromal symptoms on the early diagnosis of Parkinson’s disease. J Neurol 260:3077–3085
Conflict of interest
The authors have no financial interests that relate to research covered in this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Walter, U., Heilmann, R., Kaulitz, L. et al. Prediction of Parkinson’s disease subsequent to severe depression: a ten-year follow-up study. J Neural Transm 122, 789–797 (2015). https://doi.org/10.1007/s00702-014-1313-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-014-1313-0